Skip to content

Role of Surgery in Advanced Ovarian Cancer

Role of Surgery in Advanced Ovarian Cancer

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03980028
Enrollment
550
Registered
2019-06-10
Start date
2018-01-01
Completion date
2019-06-01
Last updated
2019-06-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian Cancer

Keywords

surgery, cancer, ovarian, advanced

Brief summary

To demonstrate that ultra-radical surgery with multiple visceral resections and high tumor burden prior to surgery independently reduces the survival of patients with advanced ovarian cancer treated with complete cytoreductive surgery.

Detailed description

Primary objective : To demonstrate that ultra-radical surgery with multiple visceral resections and high tumor burden prior to surgery independently reduces the survival of patients with advanced ovarian cancer treated with complete cytoreductive surgery. Secondary objectives: 1. Demonstrate that, in patients with advanced ovarian cancer (FIGO stage IIIC-IVB) treated by complete cytoreduction surgery, the high tumor load before surgery decreases survival. / Evaluate whether there is a sub-group of patients at risk for whom the high tumor burden prior to surgery reduces survival. 2. Demonstrate that, in patients with advanced ovarian cancer (FIGO stage IIIC-IVB) treated by complete cytoreduction surgery, the extension of carcinomatosis to the upper abdomen reduces the chances of survival. / Assess whether there is a subgroup of patients at risk for whom the extension of carcinomatosis to the upper abdomen reduces survival. 3. Demonstrate that, in patients with advanced ovarian cancer (FIGO Stage IIIC-IVB) treated by complete cytoreduction surgery, invasion of the celiac lymph nodes reduces survival rates. / Assess whether there is a subset of patients at risk where the invasion of the celiac lymph nodes reduces survival. 4. Demonstrate that, in patients with advanced ovarian cancer (FIGO stage IIIC-IVB) treated with complete cytoreduction surgery, combination with surgical procedures reduces survival. / Evaluate whether there is a sub-group of at-risk patients for whom the combination of surgical procedures with ultra-radical surgery reduces survival.

Interventions

None listed

Sponsors

Institut Bergonié
CollaboratorOTHER
Institut Paoli-Calmettes
CollaboratorOTHER
Institut du Cancer de Montpellier - Val d'Aurelle
CollaboratorOTHER
Hospital Universitario La Paz
CollaboratorOTHER
Hospital Vall d'Hebron
CollaboratorOTHER
Institut Claudius Regaud
Lead SponsorOTHER

Study design

Observational model
ECOLOGIC_OR_COMMUNITY
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* confirmed histological diagnosis of ovarian epithelial cancer * complete cytoreduction surgery

Exclusion criteria

* women under 18 years or presence of residual tumor \>2.5mm after surgery or lack of data on performed surgical procedures or surgery performed before 2008, January or after 2015, Decembrer.

Design outcomes

Primary

MeasureTime frameDescription
Patient survival4 yearspatient survival after surgery (patient record)
Evaluation of the tumor burden1 dayMeasurement of tumor size before surgery (patient record)

Secondary

MeasureTime frameDescription
Evaluation of the extension of carcinomatosis1 dayNumber of tumor nodules before surgery (patient record)
Evaluation of the invasion of celiac lymph nodes1 dayNumber of celiac lymph nodes before surgery (patient record)
Combination of surgical procedures1 dayNumber and type of combination of surgical procedures (patient record)

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026